Immunoscore

Last updated

The Immunoscore is a method to estimate the prognosis of cancer patients, based on the immune cells that infiltrate cancer and surround it. The Immunoscore has been internationally validated in colorectal cancer [1] and provides better prognostic information than the current staging system, TNM. In other malignancies the Immunoscore has not yet been validated. It is based on Jerome Galon's finding from 2006 [2] which revealed a positive association of cytotoxic and memory T cells with survival of colorectal cancer patients.

Introduction

The most common system for classifying the extent of spread of cancer is the TNM classification, which has been used for over 80 years. However, its prognostic accuracy is limited and clinical outcome can significantly vary among patients within the same tumor stage. [3] This method fails to incorporate the effects of the host immune response and focus only on the tumor cells. From the beginning of 21st century, growing evidences supports the important role of the immune system in cancer surveillance and clearance. The ability to avoid immune destruction has been introduced as a hallmark of cancer. [4] Immunoscore incorporates the effects of the host immune response into cancer classification and improves prognostic accuracy. It measures the density of two T lymphocyte populations (CD3/CD8, CD3/CD45RO or CD8/CD45RO) in the center and at the periphery of the tumor. The Immunoscore provides a score ranging from 0 (I0) when low densities of both cell types are found in both regions, to Immunoscore 4 (I4) when high densities are found in both regions. [5] The Immunoscore does not measure how the immune cells in the periphery of the tumor are organized, or the amount of B-cells, tertiary lymphoid structures and germinal centers. All of these have important roles in the immune response to colorectal [6] and other cancers. [7]

Related Research Articles

<span class="mw-page-title-main">Lymphatic system</span> Organ system in vertebrates

The lymphatic system, or lymphoid system, is an organ system in vertebrates that is part of the immune system, and complementary to the circulatory system. It consists of a large network of lymphatic vessels, lymph nodes, lymphoid organs, lymphoid tissues and lymph. Lymph is a clear fluid carried by the lymphatic vessels back to the heart for re-circulation..

<span class="mw-page-title-main">Dendritic cell</span> Accessory cell of the mammalian immune system

A dendritic cell (DC) is an antigen-presenting cell of the mammalian immune system. A DC's main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and adaptive immune systems.

<span class="mw-page-title-main">Keratin 20</span> Protein-coding gene in the species Homo sapiens

Keratin 20, often abbreviated CK20, is a protein that in humans is encoded by the KRT20 gene.

<span class="mw-page-title-main">CD40 (protein)</span> Mammalian protein found in Homo sapiens

Cluster of differentiation 40, CD40 is a type I transmembrane protein found on antigen-presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects.

Memory T cells are a subset of T lymphocytes that might have some of the same functions as memory B cells. Their lineage is unclear.

Lymphotoxin is a member of the tumor necrosis factor (TNF) superfamily of cytokines, whose members are responsible for regulating the growth and function of lymphocytes and are expressed by a wide variety of cells in the body.

Understanding of the antitumor immunity role of CD4+ T cells has grown substantially since the late 1990s. CD4+ T cells (mature T-helper cells) play an important role in modulating immune responses to pathogens and tumor cells, and are important in orchestrating overall immune responses.

<span class="mw-page-title-main">Tumor-infiltrating lymphocytes</span>

Tumor-infiltrating lymphocytes (TIL) are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis.

<span class="mw-page-title-main">CD226</span> Protein-coding gene in the species Homo sapiens

CD226, PTA1 or DNAM-1 is a ~65 kDa immunoglobulin-like transmembrane glycoprotein expressed on the surface of natural killer cells, NK T cell, B cells, dendritic cells, hematopoietic precursor cells, platelets, monocytes and T cells.

<span class="mw-page-title-main">BTLA</span> Protein-coding gene in the species Homo sapiens

B- and T-lymphocyte attenuator or BTLA is a protein that belongs to the CD28 immunoglobulin superfamily (IgSF) which is encoded by the BTLA gene located on the 3rd human chromosome. BTLA was first discovered in 2003 as an inhibitor of Th1 expansion and it became the 3rd member of the CD28 IgSF. However, its discovered ligand herpes virus entry mediator or HVEM belongs to the tumor necrosis factor receptor superfamily (TNFRSF). This finding was surprising because until the discovery of HVEM it was believed that receptors and ligands always belong to the same family.

<span class="mw-page-title-main">TNFRSF18</span> Protein-coding gene in the species Homo sapiens

Tumor necrosis factor receptor superfamily member 18 (TNFRSF18), also known as glucocorticoid-induced TNFR-related protein (GITR) or CD357. GITR is encoded and tnfrsf18 gene at chromosome 4 in mice. GITR is type I transmembrane protein and is described in 4 different isoforms. GITR human orthologue, also called activation-inducible TNFR family receptor (AITR), is encoded by the TNFRSF18 gene at chromosome 1.

<span class="mw-page-title-main">TOX</span> Protein-coding gene in the species Homo sapiens

Thymocyte selection-associated high mobility group box protein TOX is a protein that in humans is encoded by the TOX gene. TOX drives T-cell exhaustion and plays a role in innate lymphoid cell development.

<span class="mw-page-title-main">Trifunctional antibody</span> Monoclonal antibody

A trifunctional antibody is a monoclonal antibody with binding sites for two different antigens, typically CD3 and a tumor antigen, making it a type of bispecific monoclonal antibody. In addition, its intact Fc-part can bind to an Fc receptor on accessory cells like conventional monospecific antibodies. The net effect is that this type of drug links T cells and monocytes/macrophages, natural killer cells, dendritic cells or other Fc receptor expressing cells to the tumor cells, leading to their destruction.

Adoptive cell transfer (ACT) is the transfer of cells into a patient. The cells may have originated from the patient or from another individual. The cells are most commonly derived from the immune system with the goal of improving immune functionality and characteristics. In autologous cancer immunotherapy, T cells are extracted from the patient, genetically modified and cultured in vitro and returned to the same patient. Comparatively, allogeneic therapies involve cells isolated and expanded from a donor separate from the patient receiving the cells.

Colon cancer staging is an estimate of the amount of penetration of a particular cancer. It is performed for diagnostic and research purposes, and to determine the best method of treatment. The systems for staging colorectal cancers depend on the extent of local invasion, the degree of lymph node involvement and whether there is distant metastasis.

Jérôme Galon is a French biologist. He is a first class Research Director (DR1) at Institut National de la Santé et de la Recherche Médicale (INSERM).

The Immunologic Constant of Rejection (ICR), is a notion introduced by biologists to group a shared set of genes expressed in tissue destructive-pathogenic conditions like cancer and infection, along a diverse set of physiological circumstances of tissue damage or organ failure, including autoimmune disease or allograft rejection. The identification of shared mechanisms and phenotypes by distinct immune pathologies, marked as a hallmarks or biomarkers, aids in the identification of novel treatment options, without necessarily assessing patients phenomenologies individually.

<span class="mw-page-title-main">Histopathology of colorectal adenocarcinoma</span> Analysis of tissue from a biopsy or surgery to identify colorectal cancer characteristics

The histopathology of colorectal cancer of the adenocarcinoma type involves analysis of tissue taken from a biopsy or surgery. A pathology report contains a description of the microscopical characteristics of the tumor tissue, including both tumor cells and how the tumor invades into healthy tissues and finally if the tumor appears to be completely removed. The most common form of colon cancer is adenocarcinoma, constituting between 95% and 98% of all cases of colorectal cancer. Other, rarer types include lymphoma, adenosquamous and squamous cell carcinoma. Some subtypes have been found to be more aggressive.

APC Activators are a type of immunotherapy which leverages antigen-presenting cells (APCs) to drive an adaptive immune response. APC Activators are agonists to APC surface-expressed ligands that, when bound, induce the maturation and activation of APCs. Professional antigen-presenting cells – including dendritic cells, macrophages, and B cells – serve an indispensable role in the adaptive immune response through their unique ability to phagocytose, digest, and present exogenous (circulating) antigens to T cells, facilitating antigen-specific immune responses.

Epitope Detection in Monocytes (EDIM) is a technology that uses the innate immune system's mechanisms to detect biomarkers or antigens in immune cells. It is a non-invasive form of liquid biopsy, i.e. biopsy from blood, which analyzes activated macrophages (CD14+/CD16+) for disease-specific epitopes, such as tumor cell components.

References

  1. ↑ Pagès, Franck; Mlecnik, Bernhard; Marliot, Florence; Bindea, Gabriela; Ou, Fang-Shu; Bifulco, Carlo; Lugli, Alessandro; Zlobec, Inti; Rau, Tilman T. (26 May 2018). "International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study". Lancet. 391 (10135): 2128–2139. doi:10.1016/S0140-6736(18)30789-X. ISSN   1474-547X. PMID   29754777. S2CID   21680968.
  2. ↑ Galon, Jérôme; Costes, Anne; Sanchez-Cabo, Fatima; Kirilovsky, Amos; Mlecnik, Bernhard; Lagorce-Pagès, Christine; Tosolini, Marie; Camus, Matthieu; Berger, Anne (2006-09-29). "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome". Science. 313 (5795): 1960–1964. doi:10.1126/science.1129139. ISSN   1095-9203. PMID   17008531. S2CID   473931.
  3. ↑ Gao, Peng; Song, Yong-xi; Wang, Zhen-ning; Xu, Ying-ying; Tong, Lin-lin; Sun, Jing-xu; Yu, Miao; Xu, Hui-mian (2013-01-01). "Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer? Analysis of the surveilla006Ece, epidemiology, and end results (SEER) database". BMC Cancer. 13: 123. doi: 10.1186/1471-2407-13-123 . ISSN   1471-2407. PMC   3651725 . PMID   23496812.
  4. ↑ Hanahan, Douglas; Weinberg, Robert A. (2011-03-04). "Hallmarks of cancer: the next generation". Cell. 144 (5): 646–674. doi: 10.1016/j.cell.2011.02.013 . ISSN   1097-4172. PMID   21376230.
  5. ↑ Galon, Jérôme; Mlecnik, Bernhard; Bindea, Gabriela; Angell, Helen K.; Berger, Anne; Lagorce, Christine; Lugli, Alessandro; Zlobec, Inti; Hartmann, Arndt (2014-01-01). "Towards the introduction of the 'Immunoscore' in the classification of malignant tumours". The Journal of Pathology. 232 (2): 199–209. doi:10.1002/path.4287. ISSN   1096-9896. PMC   4255306 . PMID   24122236.
  6. ↑ Maoz, Asaf; Dennis, Michael; Greenson, Joel K. (2019). "The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer". Frontiers in Immunology. 10: 1884. doi: 10.3389/fimmu.2019.01884 . ISSN   1664-3224. PMC   6714555 . PMID   31507584.
  7. ↑ Siliņa, Karīna; Soltermann, Alex; Attar, Farkhondeh Movahedian; Casanova, Ruben; Uckeley, Zina M.; Thut, Helen; Wandres, Muriel; Isajevs, Sergejs; Cheng, Phil (1 March 2018). "Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma". Cancer Research. 78 (5): 1308–1320. doi: 10.1158/0008-5472.CAN-17-1987 . ISSN   1538-7445. PMID   29279354.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.